Blood and eye fluid markers in choroidal neovascularization
Looks for markers in blood and eye fluid linked to response to anti-VEGF eye treatment.
Plain-language title generated from the registry record
Registry title: Biomarkers and Choroidal Neovascularization
Key facts
- Where
- Paris and Suresnes, FranceSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT04439708, who can take part
Where in France
- Ophtalmopole Hôpital CochinParis, FranceTaking people
- Hopital FochSuresnes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut National de la Santé Et de la Recherche Médicale, France
- Trial code
- NCT04439708
- Record updated
- 7 July 2026
- Original description
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.Read full original descriptionShow less
Biomarkers Analysis of Mineralocortoid Receptor Activation in the Serum and Ocular Fluid of Patients With Choroidal Neovascularization
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
Inclusion: Patients of group 1:; Patients with type 1 choroidal neovascularization in a context of central serous chorioretinoathy or age related macular degeneration; Patients without intravitreal injection or last intravitreal injection > 3 months; Informed signed consent; Patients of group 2:; Patients without choroidal neovascularization; Patients with intraocular surgery (cataract or vitrectomy surgery); Signed consent.
Exclusion: Myocardial infarction < 12 months; Chronic renal failure; Inflammatory disease; Infectious disease :HIV, viral hepatitis, tuberculosis; Type 1 or 2 Diabetes; Patients treated by mineralocorticoid antagonist treatment; Type 2 or 3 choroidal neovascularization; Pregnant woman.